Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Rajiv P. Panikkar

Hematology Oncology | Hematology | Oncology
Geisinger Clinic
100 N Academy Ave, 
Danville, PA 
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Geisinger Clinic
100 N Academy Ave, 
Danville, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajiv Panikkar is a Hematologist Oncology specialist and a Hematologist in Danville, Pennsylvania. Dr. Panikkar is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Arterial Embolism, and Familial Colorectal Cancer.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 5 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Geisinger Medical Center
Geisinger-Bloomsburg Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

GEISINGER CLINIC
100 N Academy Ave, Danville, PA 17822

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Efatutazone, Paclitaxel
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: March 08, 2022
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 16 Less Clinical Trials

10 Total Publications

Radiation Therapy in the Last Month of Life: Association With Aggressive Care at the End of Life.
Radiation Therapy in the Last Month of Life: Association With Aggressive Care at the End of Life.
Journal: Journal of pain and symptom management
Published: August 17, 2023
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Takefumi Komiya
Oncology | Hematology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Takefumi Komiya
Oncology | Hematology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (48.8 miles away)
717-531-5638
Languages Spoken:
English
See accepted insurances

Takefumi Komiya is an Oncologist and a Hematologist in Hershey, Pennsylvania. Dr. Komiya is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Chandra P. Belani
Hematology Oncology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Chandra P. Belani
Hematology Oncology | Oncology
500 University Dr, 
Hershey, PA 
 (48.8 miles away)
717-531-6585
Languages Spoken:
English
See accepted insurances

Chandra Belani is a Hematologist Oncology specialist and an Oncologist in Hershey, Pennsylvania. Dr. Belani is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Patrick C. Ma
Hematology Oncology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Patrick C. Ma
Hematology Oncology | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (48.8 miles away)
717-531-8395
Languages Spoken:
English, Cantonese
See accepted insurances
Accepting New Patients

Patrick Ma is a Hematologist Oncology specialist and an Oncologist in Hershey, Pennsylvania. Dr. Ma is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Ma is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Panikkar's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile